aTyr Pharma, Inc. announced the resignation of David J. King, Ph.D. as Chief Scientific Officer of aTyr, effective as of December 31, 2018. Dr. King will be pursuing an opportunity as a founder of a private biotechnology company in a non-competitive area and in biology distinct from aTyr. Through the end of the year, Dr. King will assist in transition activities and recruitment of new leadership to continue aTyr’s research efforts. Dr. King will continue to serve as a scientific consultant for aTyr into 2019.